You are here

Therapeutic Advances in Ophthalmology

Therapeutic Advances in Ophthalmology

Published in Association with Vision UK

Editor-in-Chief
Joshua Cameron PhD FAAO Western University of Health Sciences College of Optometry in Pomona, CA, USA


eISSN: 25158414 | ISSN: 25158414 | Current volume: 10 | Current issue: 1

Journal Highlights

  • Launched in 2018
  • Gold open access journal
  • Listed in PubMed and freely available via PubMed Central
  • Indexed in Web of Science, Emerging Sources Citation Index (ESCI), EBSCO, ProQuest and Directory of Open Access Journals (DOAJ)
  • Rapid publishing
  • Free to publish (no article fees) until 31st December 2019. For manuscripts submitted after 1st January 2020 the APC is 1500 USD

Therapeutic Advances in Ophthalmology is a peer-reviewed open access journal delivering the highest quality articles, reviews, and scholarly comment on pioneering efforts and innovative studies across all areas of ophthalmology. Please see the Aims and Scope tab for further information.

This journal is a member of the Committee on Publication Ethics (COPE).

Submission information

Submit your manuscript at today at https://mc.manuscriptcentral.com/taop

Please see the Submission Guidelines tab for more information on how to submit your article to the journal.

Open access article processing charge (APC) information

This journal does not currently charge an article processing charge for open access publication. In the future, it is expected that an APC will be charged to ensure the long-term sustainability of the journal.

The article processing charge (APC) is payable only if your article is accepted after peer review, before it is published. The APC is subject to taxes where applicable. Tax-exempt status can be indicated by providing appropriate registration numbers when payment is requested. Please see further details here.

Contact

Please direct any queries to TAOphthalmology@sagepub.co.uk  

Therapeutic Advances in Ophthalmology delivers the highest quality peer-reviewed original research articles, reviews, and scholarly comment on pioneering efforts and innovative studies in the medical treatment of eye diseases. The journal has a strong clinical and pharmacological focus and is aimed at an international audience of clinicians and researchers in ophthalmology and related disciplines, providing an online forum for rapid dissemination of recent research and perspectives in this area.

The editors welcome original research articles across all areas of ophthalmology.
The journal publishes original research articles and review articles primarily. Original research manuscripts may include laboratory, animal or human/clinical studies – all phases. Letters to the Editor and Case Reports will also be considered.
Review articles include expert opinion/perspective reviews (including single-drug and drug class reviews), narrative reviews and therapeutic area reviews. Systematic reviews, meta-analyses, postmarketing and health economic and pharmacoeconomic reviews are also welcomed. The appropriate EQUATOR Network reporting guidelines should be followed (e.g. CONSORT for randomized, controlled trials and PRISMA for systematic reviews/meta-analyses). The journal endorses the ICMJE requirement that clinical trials are registered in a WHO-approved public trials registry at or before the time of first patient enrolment. However, consistent with the AllTrials campaign, retrospectively registered trials will be considered if the justification for late registration is acceptable.
The journal adheres to a blind review process in which the reviewer's name is routinely withheld from the author unless the reviewer requests a preference for their identity to be revealed. Manuscripts are reviewed by at least two referees; a first editorial decision is generally reached within 3 weeks of submission and Online First publication is usually within 3 weeks of Acceptance.

Editorial Board Member
Chi-Chao Chan MD National Eye Institute, National Institutes of Health, Bethesda, MD, USA
Nigel G. F. Cooper PhD University of Louisville, KY, USA
Richard D. Dix PhD Emory University School of Medicine, Atlanta, GA, USA
Donald Egan OD FAAO University of Pikeville, KY, USA
Zisis Gatzioufas MD, PhD, FMH, FEBO University Hospital Basel, Switzerland
Pearse Keane MD MSc FRCOphth MRCSI Moorfields Eye Hospital and UCL Institute of Ophthalmology, London, UK
Stuart A. Lipton PhD MD Scripps Research Institute, and University of California at San Diego, La Jolla, CA, USA
Daniel E. Maidana MD Massachusetts Eye and Ear Infirmary, Harvard Medical School, Boston, MA, USA
Mariya Moosajee MBBS PhD FRCOphth Moorfields Eye Hospital and UCL Institute of Ophthalmology, London, UK
Raymond P Najjar PhD Singapore Eye Research Institute, Singapore
Noorjahan Panjwani PhD Tufts University School of Medicine, Boston, MA, USA
Giuseppe Querques MD PhD University Vita-Salute San Raffaele Scientific Institute, Italy
Mansoor Sarfarazi PhD University of Connecticut Health Center, Farmington, CT, USA
Ronald H. Silverman PhD Columbia University Medical Center, NY, USA
Liza Sharmini Ahmad Tajudin, MD, PhD Universiti Sains Malaysia, Kota Bharu, Kelantan, Malaysia
Terri L. Young MD MBA Duke University, Durham, NC, USA
Javier Zarranz-Ventura MD, PhD, FEBO University Clinic Barcelona, Spain
Kang Zhang MD PhD University of California at San Diego School of Medicine, La Jolla, CA, USA

 Manuscript Submission Guidelines: Therapeutic Advances in Ophthalmology

  1. Open Access
  2. What do we publish?
    2.1 Aims & scope
    2.2 Article Processing Charge
    2.3 Article types
    2.4 Writing your paper
  3. Editorial policies
    3.1 Peer review policy
    3.2 Authorship
    3.3 Acknowledgements
    3.4 Funding
    3.5 Declaration of conflicting interests
    3.6 Research ethics and patient consent
    3.7 Clinical trials
    3.8 Reporting guidelines
    3.9 Data
  4. Publishing policies
    4.1 Publication ethics
    4.2 Contributor's publishing agreement
  5. Preparing your manuscript
    5.1 Word processing formats
    5.2 Artwork, figures and other graphics
    5.3 Supplementary material
    5.4 Reference style
    5.5 English language editing services
  6. Submitting your manuscript
    6.1 How to submit your manuscript
    6.2 Title, keywords and abstracts
    6.3 Information required for completing your submission
    6.4 ORCID
    6.5 Permissions
  7. On acceptance and publication
    7.1 SAGE Production
    7.2 Online publication
    7.3 Promoting your article
  8. Further information

This Journal is a member of the Committee on Publication Ethics.

This Journal recommends that authors follow the Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly Work in Medical Journals formulated by the International Committee of Medical Journal Editors (ICMJE).

All articles are listed on PubMed.

Please read the guidelines below then visit the journal’s submission site https://mc.manuscriptcentral.com/taop your manuscript. Please note that manuscripts not conforming to these guidelines may be returned. Remember you can log in to the submission site at any time to check on the progress of your paper through the peer review process.

Only manuscripts of sufficient quality that meet the aims and scope of Therapeutic Advances in Ophthalmology will be reviewed.

As part of the submission process you will be required to warrant that you are submitting your original work, that you have the rights in the work, that you are submitting the work for first publication in the Journal and that it is not being considered for publication elsewhere and has not already been published elsewhere, and that you have obtained and can supply all necessary permissions for the reproduction of any copyright works not owned by you. 

Therapeutic Advances in Ophthalmology may accept submissions of papers that have been posted on pre-print servers; please alert the Editorial Office when submitting (contact details are at the end of these guidelines) and include the DOI for the preprint in the designated field in the manuscript submission system. Authors should not post an updated version of their paper on the preprint server while it is being peer reviewed for possible publication in the journal. If the article is accepted for publication, the author may re-use their work according to the journal's author archiving policy.

If your paper is accepted, you must include a link on your preprint to the final version of your paper.

1. Open Access

Therapeutic Advances in Ophthalmology is an open access, peer-reviewed journal. Each article accepted by peer review is made freely available online immediately upon publication, is published under a Creative Commons license and will be hosted online in perpetuity.  

For general information on open access at SAGE please visit the Open Access page or view our Open Access FAQs.

Return to top

2. What do we publish?

2.1 Aims & scope

Before submitting your manuscript to Therapeutic Advances in Ophthalmology, please ensure you have read the Aims & Scope.

2.2 Article Processing Charge

Unsolicited manuscripts submitted to Therapeutic Advances in Ophthalmology after 1st January 2020 are subject to an Article Processing Charge (APC) of 1,500 USD (+VAT where applicable*) payable upon acceptance. These articles will be published under a Creative Commons Licence and will be made openly available.

*If the paying party is based in the European Union, to comply with European law, value added tax (VAT) must be added to the APC. Providing a VAT registration number will allow an institution to be exempt from paying this tax, except for UK institutions.

2.3 Article types

Therapeutic Advances in Ophthalmology considers the following kinds of article for publication:

  1. Original Research Articles, describing new experimental findings, or analyses (e.g., post hoc, subgroup, meta-analysis where an overall statistic is derived).
  2. Review Articles. The Editors wish to encourage the following types of review, but request that authors contact them in advance: (a) General reviews that provide a synthesis of an area that fits within the aims and scope of the journal;  (b) Perspective reviews - review articles that address important new areas of general interest and afford the author the opportunity to present a forward-looking perspective on the topic;  (c) Drug reviews - review articles focusing on the available evidence for the use of a particular drug or combination therapy
  3. Systematic Reviews - these should be reported according to the PRISMA reporting guidelines (please see section 3.8);
  4. Meta-analyses - these should be reported according to the PRISMA reporting guidelines (please see section 3.8);
  5. Structured case reports - outlining an interesting case, and including a full review of the pertinent literature and a section on implications for clinical care;
  6. Case series studies or clinical series - descriptive study of a small group of patients (with the same disease or receiving the same treatment) including a full review of the pertinent literature and a section on implications for clinical care;
  7. Study protocols
  8. Letters to the Editor - these should be as concise as possible and up to 1000 words.

The journal considers the results of rigorous, well-designed studies that demonstrate “no effect” or that fail to replicate previous work (“negative data”) as important to the advancement of science. Therapeutic Advances in Ophthalmology welcomes short reports on null or negative results as long as the papers are based on strong hypothesis testing.

2.4 Writing your paper

The SAGE Author Gateway has some general advice and on how to get published, plus links to further resources.

2.4.1 Making your article discoverable

When writing up your paper, think about how you can make it discoverable. The title, keywords and abstract are key to ensuring readers find your article through search engines such as Google. For information and guidance on how best to title your article, write your abstract and select your keywords, have a look at this page on the Gateway: How to Help Readers Find Your Article Online

Return to top

3. Editorial policies

3.1 Peer review policy

The journal’s policy is to obtain at least two independent reviews for each article.  Therapeutic Advances in Ophthalmology operates a conventional single-blind peer reviewing policy in which the reviewer’s name is always concealed from the submitting author.

Referees will be encouraged to provide substantive, constructive reviews that provide suggestions for improving the work and distinguish between mandatory and non-mandatory recommendations. All manuscripts accepted for publication are subject to editing for presentation, style and grammar. Any major redrafting is agreed with the author but the Editor's decision on the text is final.

The Editor or members of the Editorial Board may occasionally submit their own manuscripts for possible publication in the journal. In these cases, the peer review process will be managed by alternative members of the Board and the submitting Editor/Board member will have no involvement in the decision-making process.

3.2 Authorship

Papers should only be submitted for consideration once consent is given by all contributing authors. Those submitting papers should carefully check that all those whose work contributed to the paper are acknowledged as contributing authors.

The list of authors should include all those who can legitimately claim authorship. This is all those who:

  1. Made a substantial contribution to the concept or design of the work; or acquisition, analysis or interpretation of data,
  2. Drafted the article or revised it critically for important intellectual content,
  3. Approved the version to be published,
  4. Each author should have participated sufficiently in the work to take public responsibility for appropriate portions of the content.

Authors should meet the conditions of all of the points above. Each author should have participated sufficiently in the work to take public responsibility for appropriate portions of the content. When a large, multicentre group has conducted the work, the group should identify the individuals who accept direct responsibility for the manuscript. These individuals should fully meet the criteria for authorship.

Acquisition of funding, collection of data, or general supervision of the research group alone does not constitute authorship, although all contributors who do not meet the criteria for authorship should be listed in the Acknowledgments section. Please refer to the International Committee of Medical Journal Editors (ICMJE) authorship guidelines for more information on authorship.

3.3 Acknowledgements

All contributors who do not meet the criteria for authorship should be listed in an Acknowledgements section. Examples of those who might be acknowledged include a person who provided purely technical help, or a department chair who provided only general support.

3.3.1 Writing assistance

Individuals who provided writing assistance, e.g. from a specialist communications company, do not qualify as authors and so should be included in the Acknowledgements section. Authors must disclose any writing assistance – including the individual’s name, company and level of input – and identify the entity that paid for this assistance.

It is not necessary to disclose use of language polishing services.

Any acknowledgements should appear first at the end of your article prior to your Declaration of Conflicting Interests (if applicable), any notes and your References.

3.4 Funding

Therapeutic Advances in Ophthalmology requires all authors to acknowledge their funding in a consistent fashion under a separate heading.  Please visit the Funding Acknowledgements page on the SAGE Journal Author Gateway to confirm the format of the acknowledgment text in the event of funding, or state that: This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.

3.5 Declaration of conflicting interests

It is the policy of Therapeutic Advances in Ophthalmology to require a declaration of conflicting interests from all authors enabling a statement to be carried within the paginated pages of all published articles. Please ensure that a ‘Declaration of Conflicting Interests’ statement is included at the end of your manuscript, after any acknowledgements and prior to the references. If no conflict exists, please state that ‘The Author(s) declare(s) that there is no conflict of interest’. For guidance on conflict of interest statements, please see the ICMJE recommendations.

3.6 Research ethics and patient consent

Medical research involving human subjects must be conducted according to the World Medical Association Declaration of Helsinki.

Submitted manuscripts should conform to the ICMJE Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly Work in Medical Journals, and all papers reporting animal and/or human studies must state in the methods section that the relevant Ethics Committee or Institutional Review Board provided (or waived) approval. Please ensure that you have provided the full name and institution of the review committee, in addition to the approval number.

For research articles, authors are also required to state in the methods section whether participants provided informed consent and whether the consent was written or verbal.

Information on informed consent to report individual cases or case series should be included in the manuscript text. A statement is required regarding whether written informed consent for patient information and images to be published was provided by the patient(s) or a legally authorized representative.

Please do not submit the patient’s actual written informed consent with your article, as this in itself breaches the patient’s confidentiality. The Journal requests that you confirm to us, in writing, that you have obtained written informed consent but the written consent itself should be held by the authors/investigators themselves, for example in a patient’s hospital record. The confirmatory letter may be uploaded with your submission as a separate file.

Please also refer to the ICMJE Recommendations for the Protection of Research Participants

All research involving animals submitted for publication must be approved by an ethics committee with oversight of the facility in which the studies were conducted. The journal has adopted the Consensus Author Guidelines on Animal Ethics and Welfare for Veterinary Journals published by the International Association of Veterinary Editors

3.7 Clinical trials

Therapeutic Advances in Ophthalmology conforms to the ICMJE requirement that clinical trials are registered in a WHO-approved public trials registry at or before the time of first patient enrolment as a condition of consideration for publication. The trial registry name and URL, and registration number must be included at the end of the abstract.

3.8 Reporting guidelines

The relevant EQUATOR Network reporting guidelines should be followed depending on the type of study. For example, all randomized controlled trials submitted for publication should include a completed CONSORT flow chart as a cited figure and the completed CONSORT checklist should be uploaded with your submission as a supplementary file. Systematic reviews and meta-analyses should include the completed PRISMA flow chart as a cited figure and the completed PRISMA checklist should be uploaded with your submission as a supplementary file. The EQUATOR wizard can help you identify the appropriate guideline.

Other resources can be found at NLM’s Research Reporting Guidelines and Initiatives.

3.9 Data

SAGE acknowledges the importance of research data availability as an integral part of the research and verification process for academic journal articles.

Therapeutic Advances in Ophthalmology encourages all authors to submit any primary data used in their research articles alongside their article submissions to be published in the online version of the journal, or provide detailed information in their articles on how the data can be obtained. This information should include links to third-party data repositories or detailed contact information for third-party data sources. Data available only on an author-maintained website will need to be loaded onto either the journal’s platform or a third-party platform to ensure continuing accessibility. Examples of data types include but are not limited to statistical data files, replication code, text files, audio files, images, videos, appendices, and additional charts and graphs necessary to understand the original research. The editor may consider limited embargoes on proprietary data. The editor can also grant exceptions for data that cannot legally or ethically be released. All data submitted should comply with Institutional or Ethical Review Board requirements and applicable government regulations. For further information, please contact the editorial office at TAOphthalmology@sagepub.co.uk.

Return to top

4. Publishing policies

4.1 Publication ethics

SAGE is committed to upholding the integrity of the academic record. We encourage authors to refer to the Committee on Publication Ethics’ International Standards for Authors and view the Publication Ethics page on the SAGE Author Gateway.

4.1.1 Plagiarism

Therapeutic Advances in Ophthalmology and SAGE take issues of copyright infringement, plagiarism or other breaches of best practice in publication very seriously. We seek to protect the rights of our authors and we always investigate claims of plagiarism or misuse of published articles. Equally, we seek to protect the reputation of the journal against malpractice. Submitted articles may be checked with duplication-checking software. Where an article, for example, is found to have plagiarized other work or included third-party copyright material without permission or with insufficient acknowledgement, or where the authorship of the article is contested, we reserve the right to take action including, but not limited to: publishing an erratum or corrigendum (correction); retracting the article; taking up the matter with the head of department or dean of the author's institution and/or relevant academic bodies or societies; or taking appropriate legal action.

4.1.2 Prior publication

If material has been previously published, it is not generally acceptable for publication in a SAGE journal. However, there are certain circumstances where previously published material can be considered for publication. Please refer to the guidance on the SAGE Author Gateway or if in doubt, contact the Editor at the address given below.

4.2 Contributor's publishing agreement

Before publication SAGE requires the author as the rights holder to sign a Journal Contributor’s Publishing Agreement. Therapeutic Advances in Ophthalmology publishes manuscripts under Creative Commons licenses. The standard license for the journal is Creative Commons by Attribution Non-Commercial (CC BY-NC), which allows others to re-use the work without permission as long as the work is properly referenced and the use is non-commercial. For more information, you are advised to visit SAGE's OA licenses page.

Alternative license arrangements are available, for example, to meet particular funder mandates, made at the author’s request.

Return to top

5. Preparing your manuscript

5.1 Word processing formats

The preferred format for your manuscript is Word. Word templates are available on the Manuscript Submission Guidelines page of our Author Gateway.

5.2 Artwork, figures and other graphics

For guidance on the preparation of illustrations, pictures and graphs in electronic format, please visit SAGE’s Manuscript Submission Guidelines 

Figures supplied in color will appear in color online.

5.3 Supplementary material

This journal is able to host additional materials online (e.g. datasets, podcasts, videos, images etc) alongside the full-text of the article. These will be subjected to peer-review alongside the article.  For more information please refer to our guidelines on submitting supplementary files, which can be found within our Manuscript Submission Guidelines page.

5.4 Reference style

Therapeutic Advances in Ophthalmology adheres to SAGE Vancouver reference style. Please review the guidelines on SAGE Vancouver to ensure your manuscript conforms to this reference style.

If you use EndNote or Zotero to manage references, you can download the appropriate output style file to help format your references quickly.

EndNote: here Zotero: here

5.5 English language editing services

Authors seeking assistance with English language editing, translation, or figure and manuscript formatting to fit the journal’s specifications should consider using SAGE Language Services. Visit SAGE Language Services on our Journal Author Gateway for further information.

Return to top

6. Submitting your manuscript

6.1 How to submit your manuscript

Therapeutic Advances in Ophthalmology is hosted on SAGE Track, a web based online submission and peer review system powered by ScholarOne™ Manuscripts. Visit https://mc.manuscriptcentral.com/taop and submit your article online.

IMPORTANT: Please check whether you already have an account in the system before trying to create a new one. If you have reviewed or authored for the journal in the past year it is likely that you will have had an account created.  For further guidance on submitting your manuscript online please visit ScholarOne Online Help.

6.2 Title, keywords and abstracts

Please supply a title, short title, an abstract and keywords to accompany your article. The title, keywords and abstract are key to ensuring readers find your article online through online search engines such as Google. Please refer to the information and guidance on how best to title your article, write your abstract and select your keywords by visiting the SAGE Journal Author Gateway for guidelines on How to Help Readers Find Your Article Online

6.3 Information required for completing your submission

Provide full contact details for the corresponding author including email, mailing address and telephone numbers. Academic affiliations are required for all co-authors. These details should be presented separately to the main text of the article to facilitate anonymous peer review.

You will be asked to provide contact details and academic affiliations for all co-authors via the submission system and identify who is to be the corresponding author. These details must match what appears on your manuscript. At this stage please ensure you have included all the required statements and declarations and uploaded any additional supplementary files (including reporting guidelines where relevant).

6.4 ORCID

As part of our commitment to ensuring an ethical, transparent and fair peer review process SAGE is a supporting member of ORCID, the Open Researcher and Contributor ID. ORCID provides a unique and persistent digital identifier that distinguishes researchers from every other researcher, even those who share the same name, and, through integration in key research workflows such as manuscript and grant submission, supports automated linkages between researchers and their professional activities, ensuring that their work is recognized.

The collection of ORCID IDs from corresponding authors is now part of the submission process of this journal. If you already have an ORCID iD you will be asked to associate that to your submission during the online submission process. We also strongly encourage all co-authors to link their ORCID ID to their accounts in our online peer review platforms. It takes seconds to do: click the link when prompted, sign into your ORCID account and our systems are automatically updated. Your ORCID iD will become part of your accepted publication’s metadata, making your work attributable to you and only you. Your ORCID iD is published with your article so that fellow researchers reading your work can link to your ORCID profile and from there link to your other publications.

If you do not already have an ORCID ID please follow this link to create one or visit our ORCID homepage to learn more.

6.5 Permissions

Authors are responsible for obtaining permission from copyright holders for reproducing any illustrations, tables, figures or lengthy quotations previously published elsewhere. For further information including guidance on fair dealing for criticism and review, please visit our Frequently Asked Questions on the SAGE Journal Author Gateway.

Return to top

7. On acceptance and publication

7.1 SAGE Production

Your SAGE Production Editor will keep you informed as to your article’s progress throughout the production process. Proofs will made available to the corresponding author via our editing portal SAGE Edit, or by email to the corresponding author and should be returned promptly. Authors are reminded to check their proofs carefully to confirm that all author information, including names, affiliations, sequence and contact details are correct, and that Funding and Conflict of Interest statements, if any, are accurate. Please note that if there are any changes to the author list at this stage all authors will be required to complete and sign a form authorising the change.

7.2 Online publication

One of the many benefits of publishing your research in an open access journal is the speed to publication. With no page count constraints, your article will be published online in a fully citable form with a DOI number as soon as it has completed the production process. At this time it will be completely free to view and download for all.

7.3 Promoting your article

Publication is not the end of the process! You can help disseminate your paper and ensure it is as widely read and cited as possible. The SAGE Author Gateway has numerous resources to help you promote your work. Visit the Promote Your Article page on the Gateway for tips and advice. In addition, SAGE is partnered with Kudos, a free service that allows authors to explain, enrich, share, and measure the impact of their article. Find out how to maximize your article’s impact with Kudos.

Return to top

8. Further information

Any correspondence, queries or additional requests for information on the Manuscript Submission process should be sent to the Therapeutic Advances in Ophthalmology editorial office as follows:

TAOphthalmology@sagepub.co.uk

Return to top